The infection site release of AMPs marries the improved biocompatibility of the delivery vehicle with the unhindered activity of the free peptide, thereby reducing off-site toxicity and rapid degradation of the free peptide while maintaining high peptide concentration at the location of interest. The gene discussed is ADSL; the disease is infection.